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A battery of pain models can be used in clinical trials to investigate the efficacy and to establish the concentration- effect 
relationship of novel analgesics. This study quantified the pharmacokinetics (PK) of pregabalin after a single oral dose of 
300 mg and the pharmacodynamics (PD) on the pain tolerance threshold (PTT) of the cold pressor, electrical stimulation, the 
pressure pain model, and on the pain detection threshold of a contact heat pain model. The PK were best described using a 
one- compartment model with lag time, linear absorption, and linear elimination. The PTT of the cold pressor showed a nega-
tive linear decrease over time without pregabalin. A linear drug effect was identified on the PTT of the cold pressor test and 
an on/off effect for the electrical stimulation PTT. No PK/PD relationship could be identified on the pressure pain and heat 
pain test.
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WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
✔  The quantification of a concentration- effect relationship 
in pain is difficult, due to a highly heterogeneous patient 
population and variable levels of pain perception. Therefore, 
clinical trials should not be focused on testing only a single 
pain model, but use a multimodal approach. Additionally, 
population PK/PD modeling has been shown to increase 
the information obtained from clinical trials by better un-
derstanding an individual’s response to analgesics.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Can the information obtained from a battery of pain 
models be used to quantify a concentration- effect rela-
tionship of pregabalin in healthy subjects?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This study quantified the PK and the PD responses to 
the cold pressor and electrical stimulation pain models 
after administration of a single dose of orally administered 
pregabalin.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  This study successfully quantified the concentration- 
effect relationship of a known analgesic using a battery of 
pain models in a clinical trial with healthy subjects. This 
information can be used to inform future clinical trial de-
sign in the investigation of novel analgesics.
Study Highlights
The quantification of pain is difficult, due to high inter-
individual and intra- individual variability in the perception 
of a pain stimulus and the complexity of pain in itself (e.g., 
acute/chronic pain, nociceptive pain, and neuropathic 
pain). In analgesic drug development, the use of a single 
pain model, or pain questionnaire, during a clinical trial will 
therefore not provide a complete overview of the possible 
pharmacological mechanisms that may be involved in the 
pain reducing effects of novel analgesics.1,2 Additionally, 
the perception of pain in healthy subjects may significantly 
differ from the target patient population, which may cause 
a discrepancy in the scaling of a drug effect from a phase I 
to a phase II clinical trial.
Therefore, to objectively measure and quantify the re-
sponse of an individual to an analgesic, more than one pain 
model should be studied.3 The use of a multimodal battery 
of pain models will create a more complete overview of the 
analgesic effects, which has an advantage in discovering 
the effectiveness of drugs with an untested or novel mech-
anism of action in an early stage of drug development.3–5 
Furthermore, the outcomes of these models can be used 
to establish the concentration- effect relationship, which is 
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important to assess analgesic effects and to inform decision 
making and evidence- based dosing.6 Population non-linear 
mixed effects (NLME) pharmacokinetic/pharmacodynamic 
(PK/PD) modeling is a commonly used tool to establish this 
relationship and to quantify the drug effect over time.7–9 This 
population PK/PD relationship can, in some cases, already 
be studied in a phase I clinical trial in healthy subjects by 
expanding the amount of data that is collected beyond the 
standard of safety and tolerability end points.
The results of a battery of pain models are commonly 
studied with a mixed model analysis of variance, in which 
the time interval that needs to be studied is dependent on 
the PK of the drug of interest.5 Previously, pregabalin was 
identified as a compound that showed a significant effect 
on multiple pain models,5 and was therefore selected as 
the model compound for this population PK/PD analysis. 
Pregabalin is a gamma- aminobutyric acid analogue that 
binds to the α2- δ auxiliary subunit of voltage- gated calcium 
channels in the central nervous system.10 When pregaba-
lin binds to this channel, the influx of Ca2+ is decreased, 
causing a reduced secretion of several neurotransmitters.11 
Strong evidence suggest that the mechanism behind the 
acute effect is caused by the internalization of the Ca2+ 
channels after binding of pregabalin.12 Pregabalin is cur-
rently being used in the treatment of neuropathic pain in pa-
tients with diabetic neuropathy, spinal cord injury, and post 
herpetic neuralgia.13
The objective of this study is the quantification of the 
concentration- effect relationship after the administration of 
a single dose of 300 mg pregabalin on cold pressor, electri-
cal, pressure, and heat pain models using population NLME 
modeling in healthy subjects. The resulting population PK/
PD models will act as a proof- of- concept for the use of a 
battery of pain models to quantify the concentration- effect 
relationship of analgesics in healthy subjects.
METHODS
Study design
The study design has been previously published in full5 
and a short summary will be provided here. A two- part 
four- way crossover study was performed in healthy sub-
jects (men and women) in which the effects of intravenous 
and orally administered analgesics were studied using a 
battery of pain tests. Ethical approval was obtained from 
the Medical Ethics Committee of the Leiden University 
Medical Center. Subjects were included either in part 1 
(intravenous administration of fentanyl, phenytoin, (S)- 
ketamine, and placebo) or in part 2 (oral administration 
of imipramine, pregabalin, ibuprofen, and placebo) of the 
study. The order of administration was randomized and 
subjects completed a total of four visits, receiving one of 
the drugs listed above during each visit, with a washout 
period of 1 week between each visit, which limited any 
carry- over effect (longest t1/2 = 22.4 hour
14). A training 
session at the start of the study, during the initial screen-
ing visit, was included to reduce possible learning effects 
during the study. For the current analysis, data from only 
the placebo and pregabalin occasions (part 2) were in-
cluded. For PK assessments, blood samples were taken at 
the following time points: predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 
and 10 hours after dosing. For PD measurements, a bat-
tery of pain models was used.15 The battery consisted of a 
variety of tests eliciting electrical, mechanical, and thermal 
(contact heat and cold pressor)- pain and included a UVB 
model, the thermal grill illusion, and a paradigm for con-
ditioned pain modulation.5,15 For each test, an electronic 
visual analogue scale (eVAS) was used from which the pain 
detection threshold (PDT), the pain tolerance threshold 
(PTT), and the area under the eVAS/intensity curve were 
derived. The battery of pain models was performed for a 
total of 10 times during each visit, including two predose 
measurements up to 1 hour before dosing.
Population PK/PD model development was performed 
on the four significant pain tests after pregabalin treatment, 
as identified in ref. 5; the PTT of the cold pressor, electri-
cal stimulation (single stimulus), the pressure pain test, and 
on the PDT of contact heat (normal skin) pain test. The ac-
tual PK sampling and PD measurement times were used for 
model development.
Pharmacokinetic model development
The structural PK model development explored one, two, 
and three- compartment models. Both linear and non- 
linear (Michaelis- Menten) elimination kinetics were evalu-
ated during model development. First- order, lag time, and 
transit compartment absorption models were explored to 
describe the absorption phase. Inter-individual variability 
(IIV) was implemented following a bottom- up inclusion pro-
cedure from a ln- normal distribution. Proportional, additive, 
or a combined (proportional + additive) residual error struc-
tures were explored.16
Pharmacodynamic model development
A sequential modeling approach was applied and indi-
vidual post hoc Bayesian estimates of the developed PK 
model were added to the PD dataset. First, the existence 
of a learning/placebo effect over time was explored using 
a linear, exponential, sigmoidal maximum effect (Emax), 
Gompertz, and Bateman function on data from the placebo 
occasion only.17 Thereafter, direct and indirect effects were 
explored during model development to establish the drug 
effect of pregabalin on the pain models.7 Both linear and 
sigmoidal Emax concentration- effect relationships were 
tested.7 The drug effect was implemented in the structural 
model as additive on the baseline (direct effect models) or 
as a proportional effect on the kin or kout (turnover com-
partment models). Between occasion variability (BOV) 
was estimated between the placebo and pregabalin visits 
within an individual. The IIV and residual error analysis were 
performed using the same procedure as with PK model 
development.
Covariate analysis
After structural PK model development, allometric scal-
ing (centered around 70 kg) was tested on the volume of 
distribution (Vd; exponent = 1) and clearance (CL; expo-
nent = 0.75). Additionally, the following covariates were 
explored in both the population PK and PD models: age, 
height, sex, body mass index (BMI), fat- free mass (FFM), 
glomerular filtration rate (GFR), and serum creatinine. The 
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FFM was calculated using the Janmahasatian equation.18 
The GFR was calculated using the serum creatinine levels 
with the Cockcroft- Gault equation.19 Visualizations of the 
post hoc Bayesian estimates vs. the covariates were gen-
erated to identify possible covariate relationships. When a 
correlation (r2 > 0.5) was identified, linear, exponential, and 
power covariate relationships were formally tested in the 
model.
Model evaluation
The model evaluation was done by comparing two nested 
models on basis of the objective function value (OFV; 
−2 × log likelihood), condition number, relative standard 
errors (RSEs), and graphical evaluation. During model 
comparison, a model with one additional parameter was 
preferred over its parent model when there was a drop of 
>6.64 points in OFV (P < 0.01; one degree of freedom be-
tween two nested models). The RSE of population param-
eters should be lower than 60%, indicating the estimation 
of these parameters with sufficient precision.20 The de-
gree of model overparameterization was determined by 
the condition number, in which a low condition number is 
preferred that should not exceed 1,000.
Goodness of fit (GOF) figures consisted of the individual 
predictions (IPREDs) and population predictions (PREDs) of 
the model vs. the observations and the conditional weighted 
residuals with interactions (CWRESI) vs. PRED and time.20 
GOF figures were used to assess model appropriateness, 
adequate model fit, and identify possible structural model 
misspecifications.
Visual predictive checks (VPCs) were generated using 500 
samples with the “vpc” function in Perl- speaks- NONMEM, 
including both the fixed and random effects (IIV) to assess 
the capabilities of the model to correctly describe the pop-
ulation trend and IIV. The population PD model confidence 
interval VPCs were generated using simulations with the in-
dividual post hoc Bayesian estimates of the PK parameters. 
Internal validation was performed using a nonparametric 
bootstrap analysis of 1,000 samples.
Software
Data assembly and graphical analysis was performed in R 
(V3.4.0).21 Diagnostic and GOF plots were generated in R 
using the ggplot2 package.22 Population NLME modeling 
was performed using NONMEM version 7.3.23 Bootstrap 
and vpc analyses were performed using Perl- speaks- 
NONMEM version 4.2.0.24
RESULTS
A total of 16 subjects were included in part 2 of the study 
(oral analgesics). The subject characteristics are reported 
in Table 1. The subject population was evenly distributed 
between men and women (n = 8/8).
Pharmacokinetics
A total of 144 PK samples of pregabalin after dose admin-
istration were planned. There were four observations below 
the lower limit of quantification (of 20 μg/l) and four samples 
were missing. These eight data points were excluded from 
the analysis resulting in a total of 136 PK observations above 
the lower limit of quantification used for model building.
The PK of pregabalin was best described using a one- 
compartment model with linear elimination kinetics. The 
addition of a peripheral compartment resulted in a non-
significant decrease in OFV (ΔOFV = −2.1) and an increase 
in the condition number, a three- compartment model was 
therefore not further explored. In the one- compartment 
model, a structural misspecification was identified in the 
absorption phase. This resulted in an overestimation of 
the observations at 30 minutes after dosing. Inclusion of a 
lag time significantly improved the fit of the observations 
in the absorption phase, as well as the general fit of the 
model (ΔOFV = −27), and was thus included in the struc-
tural model. The implementation of transit compartments 
did not prove to be superior. Significant IIV could be identi-
fied on all population PK parameters, in order of inclusion: 
ka (ΔOFV = −96), lag time (ΔOFV = −22), CL (ΔOFV = −31.7), 
and Vd (ΔOFV = −18.5), all estimated with acceptable pre-
cision (highest RSE = 42.3%). A proportional residual error 
structure was best fit for purpose.
The allometric scaling of Vd and CL gave a significant drop 
in OFV (ΔOFV = −22.4 points), indicating weight- related 
changes in the CL and Vd for these subjects. The final PK 
model had a condition number of 8.14. Parameter esti-
mates of the developed PK model of pregabalin are shown 
in Table 2. The bootstrap mean and confidence intervals 
were similar to the parameter estimates. The structural PK 
model is depicted in Figure 1a. The IPRED vs. observations 
and the CWRESI vs. time are presented in Figure 2a. The 
PRED vs. observations and CWRESI vs. time are shown in 
Appendix S1. The IPRED closely followed the line of unity, 
which indicates an accurate model fit. The central trend of 
the PRED vs. observations showed a clear scatter around 
the line of unity. The scatter at the lowest observed concen-
trations all originated from the absorption phase, which was 
corrected for in the IPRED by the IIV on the lag time parame-
ter. The majority of the data in the CWRESI vs. PRED and the 
CWRESI vs. time were within the [−2,2] interval. However, a 
small bias in the CWRESI vs. time could be identified at the 
later time points, which could be due to the long half- life of 
pregabalin compared to the observation period. The confi-
dence interval VPC, showing the 95% confidence intervals 
Table 1 Subject characteristics for the 16 subjects receiving pregabalin
Demographic Mean (SD) Range
Weight (kg) 68.0 (8.22) 54.25–77.50
Height (cm) 176 (8.54) 163.5–192.5
Age (years) 21.75 (1.61) 19–25
BMI (kg/m2) 21.89 (1.60) 19.4–24.9
FFMa (kg) 50.26 (9.95) 36.62–63.26
Serum creatinine 
(μmol/l)
82.19 (12.95) 52–99
GFRb (ml/min) 112.7 (18.18) 79–149
Mean (SD) and range (min-max). BMI, body mass index; FFM, fat- free mass; 
GFR, glomerular filtration rate.
aCalculated using the Janmahasatian equation. bCalculated using the 
Cockcroft- Gault formula. Mean (SD) and range (min-max).
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around the model median and 80% prediction intervals for 
the developed model, is shown in Figure 3a. The confidence 
intervals of the pregabalin observations are in line with the 
developed model.
Pharmacodynamics
Cold pressor. A total of 291 (148 placebo and 143 
pregabalin treated) cold pressor pain measurements were 
available for model development. One individual was 
excluded from the analysis due to a continuously maximal 
PTT of 120 seconds during both the placebo and pregabalin 
treatment visit. A linear decrease in the cold pressor PTT 
over time during the placebo occasion gave a significant 
improvement (ΔOFV  =  −17.17) in the model fit. BOV on 
the baseline was included to account for the high level of 
variability between the placebo and pregabalin occasion. 
A turnover compartment with a linear decrease over time 
resulted in an OFV of 1,319. Inclusion of a drug effect gave 
a clear improvement of the model fit. A linear relationship 
between the pregabalin concentrations and the kin showed 
to be superior (ΔOFV = −88.8) over a direct effect model 
(ΔOFV = −27.3). An Emax relationship did not further improve 
the model fit (ΔOFV = −1.6) on this data, however, the use 
of additional dosing levels could better inform the full Emax 
curve.
Significant IIV was included on the baseline (ΔOFV = −15.8) 
and the kout (ΔOFV = −7.7). A proportional residual error 
was best fit for purpose. The structural model is depicted 
in Figure 1b. The IPRED vs. observations showed a clear 
scatter around the line of unity and no structural model mis-
specification could be identified in the CWRESI vs. PRED 
(Figure 2b). The PRED vs. observations showed that there 
was a large variation in this population, which was corrected 
for after inclusion of IIV, no bias in the CWRESI over time 
was identified (Appendix S1). The model parameter esti-
mates are listed in Table 3. The population parameters were 
estimated with low RSEs (<30%), with a high RSE (57.8%) 
on the slope over time. A coefficient of variation (CV) of 24% 
was estimated as BOV on the baseline, indicating that there 
is a clear difference in the baseline response within an indi-
vidual between visits. The bootstrap mean was similar to the 
parameter estimates, the 95% confidence interval resem-
bled the expected variability based on the RSE. The VPC, 
in Figure 3b, shows that there is a broad distribution of the 
variability in the confidence interval in this model, which 
could be due to the high level of IIV on the baseline (57.2%) 
and the kout (105%), which may decrease after increasing 
the sample size of the study.
Electrical stimulation. A total of 313 (160 placebo, 153 
treated) electrical stimulation pain measurements were 
available for model development. No effect over time 
in the placebo occasion was significant. Thereafter, no 
significant effect could be estimated when no variability 
in the baseline between the placebo and pregabalin 
treatment was included. After inclusion of BOV on the 
baseline, a turnover compartment with an Emax effect on 
the kin gave a significant reduction in OFV compared to 
the steady state model (ΔOFV  =  −91.5). However, a low 
half- maximal effective concentration (EC50) was estimated 
(EC50  <  1  μg/l), indicating that the maximal effect was 
already reached at the lowest pregabalin concentrations. 
Modeling the effect as an on/off effect resulted in a 
similar OFV with lower RSEs (<30%), and was, therefore, 
preferred. Inclusion of IIV on the effect parameter (θEffect) 
was significant (ΔOFV = −6.99), which allowed variability in 
drug response between individuals. A proportional residual 
error model was best fit for purpose. The structural model 
is depicted in Figure 1b. The IPRED vs. observations show 
that, despite the high variability in observations (ranging 
from 5–50 mA), the model was able to capture the individual 
response to pregabalin. The CWRESI vs. PRED shows the 
majority of the data between the [−2,2] interval with multiple 
placebo observations outside this range (Figure 2c). The 
PRED vs. observations shows that the inclusion of IIV in the 
model was needed and high variability in the population 
exists. No structural misspecification of the model was 
identified in the CWRESI vs. time (Appendix S1). Model 
parameters are shown in Table 3. Bootstrap means and 
the corresponding 95% confidence interval were similar to 
Table 2 Pharmacokinetic model population parameter estimates of 
pregabalin
Parameter Parameter estimate
Population param-
eters (RSE)
Bootstrap result 
mean [95% CI]
ka (/hour) 6.07 [42.3%] 6.77 [2.39–15.68]
Lag time (hour) 0.495 [0.39%] 0.493 [0.47–0.50]
Vd/70 kg (L) 31.1 [3.13%] 31.1 [29.25–32.64]
CL/70 kg (L/hour) 4.5 [2.53%] 4.51 [4.30–4.75]
IIV (CV, shrinkage)
ω2 ka 2.6 (353%, 8%) 2.44 [0.79–4.30]
ω2 lag time 7.09E- 5 (0.842%, 36%) 5.55E- 4 
[1.89E- 6–2.1E- 3]
ω2 Vd/F 0.0101 (10.1%, 23%) 0.009 [0.0019–0.016]
ω2 CL/F 0.00672 (8.21%, 21%) 0.00677 
[0.00031–0.014]
Residual error 
(shrinkage)
σ2 proportional 0.0146 (14%) 0.0141 [0.008–0.020]
95% CI, 95% confidence interval; CL, clearance; CV, % coefficient of vari-
ation; IIV, interindividual variability; RSE, relative standard error; Vd, volume 
of distribution.
Figure 1 Structural pharmacokinetic (PK) model (a) of oral 
pregabalin. Structural pharmacodynamic (PD) model (b) with the 
established PK/PD relationship for both the cold pressor (CP) 
and the electrical stimulation (ES) models.
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the final parameter estimates. The VPC for the electrical 
stimulation PTT is shown in Figure 3c. A high variability 
in the baseline observations can be observed but the 
data distribution is in line with the model predictions. No 
strong correlations between the parameters in both the 
cold pressor and the electrical stimulation models were 
identified (Appendix S2).
Pressure pain. A total of 291 pressure pain measurements 
were available for model development. No significant 
effect over time in the placebo occasion was identified. 
The inclusion of a linear drug effect, driven by an effect 
compartment, resulted in a small but significant decrease 
in the OFV (ΔOFV  =  −12.73) after the addition of two 
additional parameters. A proportional residual variability of 
20% was estimated and a high RSE of 84.4% on the effect 
compartment rate constant was identified. Furthermore, 
addition of IIV on the slope of the drug effect resulted 
in a CV of higher than 400%. These results indicate 
that there is high variability present within and between 
subjects and a small drug effect, causing difficulties in the 
precise estimation of the population parameter estimates. 
Therefore, model development was not continued.
Heat pain. At each time point, three heat pain tests were 
performed and the outcomes were averaged for model 
development. A total of 313 measurements were available 
for model development. A linear decrease in the heat pain 
PDT in the placebo occasion gave a significant, 7.5 points, 
decrease in the OFV (slope −0.1  °C/hour). The addition 
of a linear effect of pregabalin on the kin of a turnover 
compartment (ΔOFV = −37.1) improved the fit of the model. 
However, no significant IIV was identified and parameters 
were estimated with high RSEs (>200%). Due to the high 
variability present in the data and difficulties in accurate 
parameter estimation, model development on the heat pain 
PDT was not continued. All NONMEM model codes have 
been added in Appendix S3.
DISCUSSION
The developed PK model of pregabalin showed accurate 
model predictions for the 16 subjects in this study. The 
limited number of observations in the absorption phase 
complicated the estimation of the population parameters 
associated with the absorption. Consequently, the highest 
RSE (42.3%) and CV (353%) were on the ka, which suggests 
Figure 2 Individual model predictions vs. observations for the final pharmacokinetic model of pregabalin (a), cold pressor pain 
tolerance threshold (PTT) (b) and electrical stimulation pain tolerance threshold (c). Blue dots = pregabalin visit measurements, orange 
dots = placebo visit measurements, CWRESI = conditional weighted residuals with interaction, black solid line = line of unity, gray 
dashed line = [−2, 2] interval, black dashed line = loess fit.
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large variability between individuals on this parameter and 
difficulties in the precise estimation of this parameter. Two 
significant concentration- effect relationships, on the cold 
pressor PTT and electrical stimulation PTT, were identified 
in this study. Both population PD models were developed 
with adequate parameter precision and individual model fit. 
The highest pregabalin concentrations and PD response 
regions were underpredicted by the model, as indicated by 
the loess smoother in Figure 2. The use of additional dos-
ing levels could further improve the model and the quanti-
fication of the concentration- effect relationship over a full 
range of concentrations.
Our developed structural PK model corresponds with pre-
viously published models in terms of model structure and 
Figure 3 Visual predictive checks of 500 samples of the population pharmacokinetic (PK) (a), the cold pressor pain tolerance 
threshold (PTT) (b), and the electrical stimulation PTT (c) after administration of a single oral dose of 300 mg pregabalin. For the 
pharmacodynamic outcomes, the left figure indicates the placebo occasion, the right figure indicates the pregabalin treated occasion. 
Black dots = observations, black dashed lines = 80% confidence interval (CI) and median of the observations, red shaded area = 95% 
CI of the median prediction, blue shaded area = 95% CI of the 10th and 90th percentiles.
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rapid absorption of pregabalin after a lag time.25,26 The re-
search performed by Hong et al.27 investigated different 
structural oral absorption models for pregabalin in which 
they reported that a first- order absorption process did not 
suffice. However, in our developed PK model, the imple-
mentation of multiple transit compartments, which was sug-
gested by Hong et al.,27 to fit the absorption phase did not 
prove to be superior over a first- order absorption with lag 
time. Additional sampling in the absorption phase, between 
0 and 1 hour after dosing, could improve the characteri-
zation of the absorption phase of pregabalin, which would 
allow for a better comparison with previous analyses. The 
use of GFR in healthy subjects as a covariate on CL was also 
suggested by Hong et al.27 However, this could not be con-
firmed in this study, which may be explained by our inclu-
sion of the allometric relationship of weight on CL, as there 
is multicollinearity between body weight and the Cockroft- 
Gault derived GFR, or the low sample size used in this study. 
The inclusion of allometric scaling on the Vd and CL of pre-
gabalin gave a significant drop in OFV. No other covariate re-
lationships were identified in the developed PK/PD models. 
This could be due to the low level of diversity between the 
included subjects (young, healthy, and normal weight) in this 
population, which may hinder the identification of significant 
covariates.
In the development of analgesics, pain models supple-
ment to the level of information from clinical trials as they 
provide a more objective marker for pain. A battery of pain 
models, as used in this study, can be used to fully explore 
the potential analgesic effects for different types of pain and 
to follow the analgesic effect over time. Intervisit variabil-
ity on the baseline, which was confirmed by the significant 
decrease in OFV after inclusion of the BOV in both PK/PD 
models, showed that the baseline response to a pain model 
between two visits of the same individual could differ sig-
nificantly. This indicates that the addition of multiple base-
line values before drug administration could give a better 
prediction of the response at the day of testing, thereby im-
proving the quality of the data that is collected.
Out of the four originally planned PK/PD models, we were 
able to quantify the concentration- effect relationships on 
only two pain models. The pressure stimulation PTT and the 
heat PDT showed a high degree of intra- individual and IIV 
and only a small drop in the OFV after inclusion of a drug 
effect. All four pain models were previously identified as 
significantly different from placebo in a mixed model anal-
ysis of variance, using the pooled data of the first 5 hours 
after pregabalin dosing (P value cold pressor PTT <0.0001, 
P value electrical stimulation PTT = 0.0121, P value pressure 
stimulation PTT = 0.0052, and P value heat (normal skin) 
PDT = 0.0049).5 The different handling of the placebo data 
in a mixed model analysis of variance, which increases the 
residual variability, and the limited improvement in outcome 
(e.g., 4.1% for the heat PDT) could be possible causes for 
the lower level of significance we identified in this population 
NLME analysis.
A previously performed study by Byon et al.28 stud-
ied the effects of pregabalin on self- assessed daily pain 
scores and the end- of- treatment patient global impres-
sion of change in patients with fibromyalgia. In that study, 
pregabalin was able to significantly lower the pain scores 
compared to placebo. They estimated a dose of 174 mg/
day that reached 50% of the maximal effect in reducing 
the pain scores and 228 mg for the global impression of 
change scores. They identified susceptibility to the effect 
of pregabalin between different age groups (<40, 40–60, 
and >60 years). Due to the limited range of age in our 
study, this covariate was not identified as a significant pre-
dictor of the effect in our study. The disadvantage of the 
use of these pain scores is the limited improvement (1.5 
point decrease on a 10- point scale) and the long duration 
of studies (>100 days), which is needed in order to assess 
the successful analgesic effects.28 Incorporating results 
from a battery of pain models in early clinical development 
Table 3 Pharmacodynamic model parameter estimates of cold pressor PTT and electrical stimulation PTT
Parameter Cold pressor PTT Electrical stimulation PTT
Turnover model population 
parameters (RSE)
Bootstrap result mean 
[95% CI]
Turnover model population 
parameters (RSE)
Bootstrap result mean 
[95% CI]
Baseline 16.9 seconds (16.8%) 17.0 [12.6–22.6] 19.1 mA (7%) 19.2 [16.36–22.06]
kout 0.39/hour (21%) 0.39 [0.18–0.64] 0.494/hour (24%) 0.50 [0.28–0.77]
Slope over time −0.07 seconds/hour (57.8%) −0.08 [−0.16–0.04] – –
Slope pregabalin 0.135 1/mg/L (16.7%) 0.143 [0.09–0.20] – –
Effect pregabalin – – 0.322 (18%) 0.326 [0.215–0.450]
IIV 
(CV, shrinkage)
IIV 
(CV, shrinkage)
ω2 BOV baseline 0.057 (24.2%, 27%) 0.060 [0.01–0.15] 0.122 (22%, 2%) 0.116 [0.070–0.172]
ω2 baseline 0.283 (57.2%, 2%) 0.267 [0.056–0.50] – –
ω2 kout 0.738 (105%, 19%) 0.715 [0.01–2.46] – –
ω2 effect – – 0.187 (70, 25%) 0.20 [0.02–0.60]
Residual error 
(shrinkage)
Residual error 
(shrinkage)
σ2 proportional 0.041 (6%) 0.041 [0.032–0.050] 0.0143 (6%) 0.0144 [0.010–0.019]
CI, confidence interval; CV, % coefficient of variation; IIV, interindividual variability; PTT, pain tolerance threshold; RSE, relative standard error.
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may link the short- term analgesic effects with long- term 
drug response in patients.
The developed population PK/PD models on the PTT of 
the cold pressor and the electrical stimulation test gives 
additional insight in the quantification of the analgesic 
concentration- effect of pregabalin that could not be ob-
tained using solely a mixed model analysis of variance. In 
this clinical study, pregabalin was administered as a single 
dose. Studying the drug effect over a broad dose range 
would enable an improved quantification of an Emax rela-
tionship and it would allow for better extrapolation to new 
dosing regimens. The development of these PK/PD models 
would be highly preferable in the case of a first- in- human 
trial, where early- stage identification of analgesic effects 
can improve the assessment of the viability of a compound, 
which can be used to inform the trial design of future clinical 
studies.
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